SUMMARY Myo-inositol was given orally to nine multiple sclerosis patients and nine healthy control subjects. Pattern In a preliminary report Holm'0 showed that 27% of patients with multiple sclerosis appeared to metabolise myo-inositol abnormally: when myo-inositol was added to their sera a large change in redox potential occurred compared with controls. Altered myo-inositol metabolism in diabetes mellitus has also been proposed as a cause of altered nerve conduction." We decided to pursue a possible role of myo-inositol in multiple sclerosis by: (I) examining the electrophysiological effects of orallyadministered myo-inositol in multiple sclerosis patients and control subjects and (2) measuring myoinositol in the cerebrospinal fluid (CSF) in multiple sclerosis and control patients.
ponents of plasma membrane and myelin.' They have achieved recent recognition for roles in metabolic regulation of nervous tissue2 and in receptor physiology.3
In a preliminary report Holm'0 showed that 27% of patients with multiple sclerosis appeared to metabolise myo-inositol abnormally: when myo-inositol was added to their sera a large change in redox potential occurred compared with controls. Altered myo-inositol metabolism in diabetes mellitus has also been proposed as a cause of altered nerve conduction." We decided to pursue a possible role of myo-inositol in multiple sclerosis by: (I) examining the electrophysiological effects of orallyadministered myo-inositol in multiple sclerosis patients and control subjects and (2) measuring myoinositol in the cerebrospinal fluid (CSF) in multiple sclerosis and control patients. better. We tested all subjects in an identical manner with the same ambient lighting and at approximately the same time of day for each subject using a Nicolet CA 1000 Clinical Averager System. The reversing black and white checker board pattern was one metre from the subject's eye, with each square subtending 27 minutes of arc. Luminance was 700 cd/M2 for white and 0 7 cd/M2 for dark squares. The pattern reversed at 1-88 times/second. Each eye was tested separately twice at each testing session, with 100 repetitions per determination. Bandpass filter settings were 5-100Hz.
Scalp disk electrodes were used with O.-C. derivation; impedances were 2-4 k ohms. Printout was on an X-Y plotter.
The major positive wave was clearly identified in each case. N,, P2 and N2 peaks were identified (fig 1) . Latency was from the time from the stimulus trigger to the peak of the P2 wave. Amplitude was defined as the voltage difference between the N, and P2 peaks. Duration was the N2-N, peak to peak time difference. When values differed slightly in the 2 tests per determination, the values were averaged. The area "under the curve" was approximated by joining N ,, N2 and P2 points with straight lines and determining the area of the triangle so formed.
Each subject had four testing sessions. In Trial 1 the subject took no medication. Trial 2 testing was performed after 500mg of myo-inositol was taken daily by mouth for 2 weeks. Trial 3 was performed after 1000 mg daily for two weeks and Trial 4 after no medication for two weeks. Myoinositol was given in gelatin capsules containing 500 mg. A single dose was given each morning; pattern reversal evoked potential testing was performed between 3-6 hours after the last dose.
Statistical treatment of Part A utilised two sequential analyses of variance (ANOVAs) which were performed on each of the four dependent variables, that is latency, amplitude, duration and area subtended by the N 1 P2 N2 complex. In each case the first analysis was a 2 x 2 x 2 ANOVA in which the respective independent variables were group (multiple sclerosis versus control), eye (left versus right) and Trial (I versus 4). The purpose of this preliminary analysis was to detect any significant change between the initial medication free trial (Trial 1) and the subsequent trial without medi-hysterical paralysis (2), Guillain-Barre syndrome (1), motor cation (Trial 4). If Trials 1 and 4 proved to be comparable, neuron disease (2), cerebral infarction (2), encephalitis (2) the respective scores were averaged and the average was Bell's palsy (1) and atypical facial pain (1). treated as the subject's score for 0 mg of myo-inositol. The Samples of CSF (0 5-07 ml) were diluted to 3-0 ml with second analysis for each dependent variable was a 2 x 2 x 3 distilled water and deproteinised by adding 0 15 ml of tri-ANOVA with group. eye and myo-inositol dose as the chloroacetic acid (100 g/100 ml). Protein was precipitated by respective independent variables. ln this ANOVA the three centrifugation and the supernatant was adjusted to pH 7-8 levels of the dose factor were 0 mg (Trials 1 and 4), 500 mg by treatment with Dowex 1-x8 (OH) ion-exchange resin. (Trial 2) and 1000 mg (Trial 3). Trend analyses of the dose Aliquots of the supernatant solutions were placed in glass factor were conducted so that a statistically significant vials and dried overnight at 55-60°C. Dried samples were effect could be attributed to either its linear or quadrantic dissolved in dimethylsulfoxide (0 1 ml) and 04 ml of silcomponent.
yating reagent (7-0 ml pyridine, 2-0 ml hexamethyldisilazene (B) CSF inositol determination and 1-0 ml trimethylchlorosilane) was added. The reaction We collected CSF from 55 multiple sclerosis patients (mean was allowed to proceed at 22°C for 20 minutes. The byage 36 years, SD 10 years; 20 males and 35 females) and 21 products in the reaction mixture were removed by centrifupatients who did not have multiple sclerosis (mean age 37 gation. 5-10 g1 aliquots of reaction mixture were then chroyears, SD 13 years, 10 males and 11 females). Most of the matographed on a glass column using a nitrogen carrier non-multiple sclerosis patients were undergoing myelo-(45 ml/min) in a Tracor Gas Chromatograph model 560 graphy for lumbar or cervical disk disease. Other diagnoses with a hydrogen flame detector. Temperatures of inlet, included: migraine (1), benign intracranial hypertension (1), detector and outlet were 205, 210 and 220°C respectively. Since latencies on Trials 1 and 4 were equivalent, these data were averaged to provide an estimate of latency in the unmedicated state. An analysis of variance was then performed to evaluate the effect of 0 269 (Trials 1 and 4 pooled), 500 (Trial 2) and 1000 (Trial 3) mg of myo-inositol on P2 latency. The only significant effect was the main effect for group, F(l, 16) = 16-22, p = 0 01 1, which again reflects the greater latency in the multiple sclerosis group. There was neither a significant dose effect, F < 1, nor a significant Group x Dose interaction, F(2,32), p > 0 35. Thus the latencies are not significantly altered by 500 or 1000 mg doses of myo-inositol. Amplitude Mean P2 amplitudes for the multiple sclerosis and control groups on each of the four Trials are shown in fig 3(a) . Amplitude data were analysed in the same manner as the latency data. Preliminary analysis from the medication-free conditions ( Our main finding is that multiple sclerosis patients and control subjects differ significantly in the alteration of mean values of P2 amplitude, duration and area associated with myo-inositol administration. Furthermore the differences between the two groups are dose-dependent in a linear manner. It appears to us these findings reflect a differential response to myoinositol on either conduction or on synaptic activity.
Although conduction velocity does not appear to be increased, reversal of conduction block in some demyelinated axons in the visual pathway could produce an enhanced P2 response. In view of the acute reversal of its effect, it seems unlikely the administered myo-inositol altered the physical structure of the axon to correct the transmembrane capacitance and resistance'5 or impedence mismatch'617 causing the conduction block. Hawthorne and Kai' proposed phosphoinositides play a role in ion channel gating. Although this has never been proven, a mechanism involving turning off sodium influx '8 Proposing a synaptic effect of myo-inositol raises the controversial topic of altered synaptic activity in multiple sclerosis.' 9 -26 It is still unsettled as to whether there is a "synaptic blocking factor" in multiple sclerosis, although there is some evidence for altered synaptic function produced by multiple sclerosis sera. '9-222425 Eisen et a126 also found altered neuromuscular transmission in multiple sclerosis.
Recent biochemical studies have revealed a prominent role for inositol phospholipids in the function of numerous types of receptors.3 5 When specific postsynaptic receptors are activated, phospholipase C hydrolyses phosphoinositides. One product, inositol triphosphate, is thought to function as a "second
